Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals

Cancer Letters

Volumn 265, Issue 2, 2008, Pages 307-317

  Zhu, Jian quan ^a,b   Zhong, Wen zhao ^b   Zhang, Guo chun ^b   Li, Rong ^b   Zhang, Xu chao ^b   Guo, Ai lin ^b   Zhang, Yi fang ^b   An, She juan ^b   Mok, Tony S ^c   Wu, Yi long ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Autophosphorylation; Epidermal growth factor receptor; Mutation; Non small cell lung cancer; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DOWNSTREAM PROCESSING; EMBRYO; EXON; FEMALE; GENE DELETION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INHIBITION KINETICS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; PATIENT SELECTION; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; EXONS; FEMALE; GENES, ERBB-1; HUMANS; IMMUNOBLOTTING; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 43949094139     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.02.064     Document Type: Article

References (42)

1. Breathnach O.S., Freidlin B., Conley B., Green M.R., Johnson D.H., Gandra D.R., et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J. Clin. Oncol. 19 (2001) 1734-1742
2. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353 (2005) 133-144
3. Takano T., Ohe Y., Sakamoto H., Tsuta K., Matsuno Y., Tateishi U., et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23 (2005) 6829-6837
4. Shigematsu H., and Gazdar A.F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int. J. Cancer 118 (2006) 257-262
5. Wu Y.L., Zhong W.Z., Li L.Y., Zhang X.T., Zhang L., Zhou C.C., et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J. Thorac. Oncol. 2 (2007) 430-439
6. Mu X.L., Li L.Y., Zhang X.T., Wang M.Z., Feng R.E., Cui Q.C., et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer. Clin. Cancer Res. 11 (2005) 4289-4294
7. Riely G.J., Politi K.A., Miller V.A., and Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin. Cancer Res. 12 (2006) 7232-7241
8. Carey K.D., Garton A.J., Romero M.S., Kahler J., Thomson S., Ross S., et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib. Cancer Res. 66 (2006) 8163-8171
9. Johnson B.E., and Janne P.A. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res. 65 (2005) 7525-7529
10. Lynch T.J., Bell D.W., Sordella R., Gurbhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
11. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
12. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101 (2004) 13306-13311
13. Riely G.J., Pao W., Pham D., Li A.R., Rizvi N., Venkatraman E.S., et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 12 (2006) 839-844
14. Jackman D.M., Yeap B.Y., Sequist L.V., Lindeman N., Holmes A.J., Joshi V.A., et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin. Cancer Res. 12 (2006) 3908-3914
15. Hirsch F.R., Varella-Garcia M., Cappuzzo F., McCoy J., Bemis L., Xavier A.C., et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann. Oncol. 18 (2007) 752-760
16. Uchida A., Hirano S., Kitao H., Ogino A., Rai K., Toyooka S., et al. Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Sci. 98 (2007) 357-363
17. Zhang X.T., Li L.Y., Mu X.L., Cui Q.C., Chang X.Y., Song W., et al. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann. Oncol. 16 (2005) 1334-1342
18. Zhang G.C., Lin J.Y., Wang Z., Zhou Q., Xu C.R., Zhu J.Q., et al. Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients. Clin. Oncol. (R. Coll. Radiol.) 19 (2007) 499-506
19. Sordella R., Bell D.W., Haber D.A., and Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305 (2004) 1163-1167
20. Sato M., Vaughan M.B., Girard L., Peyton M., Lee W., Shames D.S., et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res. 66 (2006) 2116-2128
21. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 23 (2005) 2513-2520
22. Paz-Ares L., Sanchez J.M., Garcia-Velasco A., Massuti B., Lopez-Vivanco G., Provencio M., et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J. Clin. Oncol. (Meeting Abstracts) 24 (2006) 7020
23. Sunaga N., Tomizawa Y., Ya nagitani N., Iijima H., Kaira K., shimizu K., et al. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer (Amsterdam, Netherlands) 56 (2007) 383-389
24. Sutani A., Nagai Y., Udagawa K., Uchida Y., Koyama N., Murayama Y., et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br. J. Cancer 95 (2006) 1483-1489
25. Inoue A., Suzuki T., Fukuhara T., Maemondo M., Kimura Y., Morikawa N., et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J. Clin. Oncol. 24 (2006) 3340-3346
26. Asahina H., Yamazaki K., Kinoshita I., Sukoh N., Harada M., Yokouchi H., et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br. J. Cancer 95 (2006) 998-1004
27. Costa D.B., Kobayashi S., Tenen D.G., and Huberman M.S. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer (Amsterdam, Netherlands) 58 (2007) 95-103
28. Chen Y.R., Fu Y.N., Lin C.H., Yang S.T., Hu S.F., Chen Y.T., et al. Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 25 (2006) 1205-1215
29. Jiang J., Greulich H., Janne P.A., Sellers W.R., Meyerson M., and Griffin J.D. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. 65 (2005) 8968-8974
30. Mukohara T., Engelman J.A., Hanna N.H., Yeap B.Y., Kobayashi S., Lindeman N., et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J. Natl. Cancer Inst. 97 (2005) 1185-1194
31. Fu Y.N., Yeh C.L., Cheng H.H., Yang C.H., Tsai S.F., Huang S.F., et al. EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy. Oncogene (2007) 10.1038/sj.onc.1210684
32. Tracy S., Mukohara T., Hansen M., Meyerson M., Johnson B.E., and Janne P.A. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 64 (2004) 7241-7244
33. Costa D.B., and Kobayashi S. Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?. Br. J. Cancer 96 (2007) 399
34. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba II., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 97 (2005) 339-346
35. Na II., Rho J.K., Choi Y.J., Kim C.H., Koh J.S., Ryoo B.Y., et al. Clinical features reflect exon sites of EGFR mutations in patients with resected non-small-cell lung cancer. J. Korean Med. Sci. 22 (2007) 393-399
36. Hirsch F.R., Varella-Garcia M., Bunn P.A., Franklin W.A., Dziadziuszko R., Thatcher N., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol. 24 (2006) 5034-5042
37. Hirata A., Hosoi F., Miyagawa M., Ueda S., Naito S., Fujii T., et al. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res. 65 (2005) 4253-4260
38. Yauch R.L., Januario T., Eberhard D.A., Cavet G., Zhu W., Fu L., et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res. 11 (2005) 8686-8698
39. Uramoto H., and Mitsudomi T. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?. Br. J. Cancer 96 (2007) 857-863
40. Kobayashi S., Boggon T.J., Dayaram T., Jane P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352 (2005) 786-792
41. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2 (2005) e73
42. Morgillo F., Bareschino M.A., Bianco R., Tortora G., and Ciardiello F. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation 75 (2007) 788-799